P3 Health Partners Inc. (PIII)

P3 Health Partners Inc. (NASDAQ:PIII ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Amir Bacchus - Co-Founder, Chief Medical Officer & Director Aric Coffman - CEO, President & Director Leif Pedersen - Chief Financial Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets, LLC, Research Division David Michael Larsen - BTIG, LLC, Research Division Joshua Richard Raskin - Nephron Research LLC Ryan M. Langston - TD Cowen, Research Division Ryan K.

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.23 per share versus the Zacks Consensus Estimate of a loss of $3.29. This compares to a loss of $7.5 per share a year ago.

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2025. “Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan,” said Aric Coffman, CEO of P3. “While we faced prior period headwinds, we've successfully managed medical cost trends to remain flat while imp.

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for second quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, August 14, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/4:30pm ET the same day. Title & Webcast P3 Health Sec.

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

After losing some value lately, a hammer chart pattern has been formed for P3 Health Partners (PIII), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

P3 Health Partners Inc. (NASDAQ:PIII ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ryan Halstead - Managing Director, Gilmartin Group LLC, IR Aric Coffman - CEO Leif Pedersen - CFO Amir Bacchus - Chief Medical Officer Conference Call Participants Josh Raskin - Nephron Research Ryan Langston - TD Cowen Operator Good day, and welcome to the P3 Health Partners First Quarter 2025 Earnings Conference Call. All participants will be in listen-only-mode.

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.28 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $8 per share a year ago.

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance. “Our physician-led care enablement model continues to differentiate P3, delivering meaningful improvements in quality measures and cost management through deeper provider partnerships,” said Aric Coffman, CEO of.